383 related articles for article (PubMed ID: 27158140)
21. Novel nitric oxide-releasing spirolactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer.
Li D; Han T; Tian K; Tang S; Xu S; Hu X; Wang L; Li Z; Hua H; Xu J
Bioorg Med Chem Lett; 2016 Sep; 26(17):4191-6. PubMed ID: 27491707
[TBL] [Abstract][Full Text] [Related]
22. Novel quinoline derivatives carrying nitrones/oximes nitric oxide donors: Design, synthesis, antiproliferative and caspase-3 activation activities.
Abdelbaset MS; Abdel-Aziz M; Abuo-Rahma GEA; Abdelrahman MH; Ramadan M; Youssif BGM
Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800270. PubMed ID: 30500087
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
[TBL] [Abstract][Full Text] [Related]
24. A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.
Xu S; Yao H; Luo S; Zhang YK; Yang DH; Li D; Wang G; Hu M; Qiu Y; Wu X; Yao H; Xie W; Chen ZS; Xu J
J Med Chem; 2017 Feb; 60(4):1449-1468. PubMed ID: 28165738
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.
Xu J; Yang J; Ran Q; Wang L; Liu J; Wang Z; Wu X; Hua W; Yuan S; Zhang L; Shen M; Ding Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4741-4. PubMed ID: 18644718
[TBL] [Abstract][Full Text] [Related]
27. Hydrogen sulfide releasing oridonin derivatives induce apoptosis through extrinsic and intrinsic pathways.
Li H; Mu J; Sun J; Xu S; Liu W; Xu F; Li Z; Xu J; Hua H; Li D
Eur J Med Chem; 2020 Feb; 187():111978. PubMed ID: 31877536
[TBL] [Abstract][Full Text] [Related]
28. Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.
Bao N; Ou J; Xu M; Guan F; Shi W; Sun J; Chen L
Eur J Med Chem; 2017 Sep; 137():88-95. PubMed ID: 28558333
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, biological evaluation and cellular localization study of fluorescent derivatives of Jiyuan Oridonin A.
Zhou C; Zhang JY; Liu HB; Tian XY; Liu Y; Wang YL; Zheng ZJ; Wang N; Wang ZJ; Xu X; Liu HM; Ke Y
Eur J Med Chem; 2022 Feb; 229():114048. PubMed ID: 34954589
[TBL] [Abstract][Full Text] [Related]
30. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Velázquez C; Das D; Suresh MR; Knaus EE
Bioorg Med Chem; 2008 Nov; 16(22):9694-8. PubMed ID: 18930406
[TBL] [Abstract][Full Text] [Related]
31. Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities.
Cheng W; Huang C; Ma W; Tian X; Zhang X
Mini Rev Med Chem; 2019; 19(2):114-124. PubMed ID: 28425866
[TBL] [Abstract][Full Text] [Related]
32. Novel anticancer hybrids from diazen-1-ium-1,2-diolate nitric oxide donor and ROS inducer plumbagin: Design, synthesis and biological evaluations.
Bao N; Ou J; Li N; Zou P; Sun J; Chen L
Eur J Med Chem; 2018 Jun; 154():1-8. PubMed ID: 29772386
[TBL] [Abstract][Full Text] [Related]
33. Oridonin inhibits BxPC-3 cell growth through cell apoptosis.
Xu B; Shen W; Liu X; Zhang T; Ren J; Fan Y; Xu J
Acta Biochim Biophys Sin (Shanghai); 2015 Mar; 47(3):164-73. PubMed ID: 25651847
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A.
Liu HC; Qiao LM; Zheng W; Xiang ZB; Chen HS; Yu SC; Zhang DZ; Wang T; Zhang YF; Jin YS
Anticancer Agents Med Chem; 2020; 20(10):1241-1249. PubMed ID: 32116205
[TBL] [Abstract][Full Text] [Related]
36. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
37. Design and Synthesis of C-19 Isosteviol Derivatives as Potent and Highly Selective Antiproliferative Agents.
Luan T; Cao LH; Deng H; Shen QK; Tian YS; Quan ZS
Molecules; 2018 Dec; 24(1):. PubMed ID: 30598028
[TBL] [Abstract][Full Text] [Related]
38. Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.
Li D; Han T; Liao J; Hu X; Xu S; Tian K; Gu X; Cheng K; Li Z; Hua H; Xu J
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563888
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological mechanisms research on 1,2,3-triazole derivatives of Jiyuan Oridonin A.
Ke Y; Wang W; Zhao LF; Liang JJ; Liu Y; Zhang X; Feng K; Liu HM
Bioorg Med Chem; 2018 Sep; 26(17):4761-4773. PubMed ID: 30143365
[TBL] [Abstract][Full Text] [Related]
40. O
Li Q; Zou P; Sun J; Chen L
Eur J Med Chem; 2018 Jan; 143():732-744. PubMed ID: 29220794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
